The GBM AGILE story
GBM AGILE is not just a science story; it's a story of courage and humanity. Find out how this adaptive clinical trial for an aggressive form of brain cancer was brought about by a global network of experts who wanted to do something different, something historic, to accelerate new treatments to people with brain cancer.
Early in 2015, a group of senior scientists and clinicians from around the world, including Australia, the US and China, came together in an unprecedented global collaboration to take action on one of the world’s deadliest diseases. That disease is the deadliest form of brain cancer, called glioblastoma multiforme, or GBM.
Of those diagnosed, only around 5% will live for five years and most will die within a year. These appalling survival statistics have remained virtually unchanged for three decades.
From this, and other meetings, a 130-strong network of experts from around the world has been formed, who decided enough is enough; patients need radical action now and this is the moment to drive forward great change to make it happen.
The innovation comes from a determination by this group to effect great change and what they call a 'coalition of the willing', which is really around a value system of integrity and the desire to serve the needs of patients over the needs of science.
Catherine Stace, CEO, Cure Brain Cancer Foundation
Driven not by financial motivation but by fierce compassion, these experts have come together, stepped out of their hierarchy and volunteered their time to find an innovative solution to get new treatments to patients faster.
Boy, why wouldn't you want to get involved when we could change the world?
Dr Anna Barker, GBM AGILE Executive Committee
They have designed a global adaptive clinical trial platform called GBM AGILE, a new approach which can be used to test multiple drugs on a greater number of patients in a highly compressed timeframe, and for a fraction of the cost of a traditional clinical trial.
They have re-engineered the medical research system using design thinking to make it work better for patients.
They have challenged thinking and disrupted the status quo. The result is a new system of clinical research which could transform the way new treatments are developed for diseases globally.
They have achieved this through the power of collaboration, innovation, ingenuity, daring greatly, fierce compassion and determination. In doing so they are not only advancing science but also evolving humanity.
This is the biggest international collaboration in the history of brain cancer research; this is the moment.
This is our time....so let's do this
Prof Webster Cavenee, GBM AGILE Executive Committee